Gene Symbol | OGN |
---|---|
Entrez Gene | 4969 |
Alt Symbol | OG, OIF, SLRR3A |
Species | Human |
Gene Type | protein-coding |
Description | osteoglycin |
Other Description | corneal keratan sulfate proteoglycan|mimecan|mimecan proteoglycan|osteoinductive factor |
Swissprots | Q9UNK5 Q6FIB0 Q9UF90 P20774 |
Accessions | AAD40453 AAF19364 CAD67633 EAW62818 EAW62819 EAW62820 P20774 AF086912 AAP97142 AF088023 AF100758 AAD43022 AF173383 AAQ13624 AF202167 AAF69109 AI424992 AK075521 BAG52162 AK129845 AK289628 BAF82317 AK295433 BAG58375 AL110267 CAB53706 AL133114 CAB61417 AM392813 CAL37691 AM392942 CAL37820 BC037273 AAH37273 BC095443 AAH95443 BG772245 BX646984 CR533516 CAG38547 DQ891227 ABM82153 DQ894412 ABM85338 NM_014057 NP_054776 NM_033014 NP_148935 NM_024416 |
Function | Induces bone formation in conjunction with TGF-beta-1 or TGF-beta-2. |
Subcellular Location | Secreted, extracellular space, extracellular matrix {ECO:0000250}. |
Tissue Specificity | Bone. |
OGN-Over-expression-Lysate - LY10099a from Abgent, a WuXi AppTec company
|
||||||||
OGN 293T Cell Transient Overexpression Lysate(Denatured) - H00004969-T01 from Acris Antibodies
|
||||||||
OGN 293 Cell Lysate - 407300 from ABBIOTEC
|
||||||||
OGN 293 Cell Lysate - 402792 from ABBIOTEC
|
||||||||
Mimecan/OIF Overexpression Lysate (Denatured) - H00004969-T01 from Novus Biologicals
|
||||||||
Mimecan/OIF Overexpression Lysate (Native) - NBL1-13917 from Novus Biologicals
|
||||||||
Mimecan/OIF Overexpression Lysate (Native) - NBL1-13918 from Novus Biologicals
|
||||||||
Osteoglycin (h): 293 Lysate - sc-129364 from Santa Cruz Biotechnology
|
||||||||
Osteoglycin (h4): 293T Lysate - sc-170582 from Santa Cruz Biotechnology
|
||||||||
OGN Over-expression Lysate Product - GWB-F8901E from Genway Biotech
|
||||||||
OGN Over-expression Lysate Product - GWB-132F6D from Genway Biotech
|
||||||||
Mimecan/OIF Overexpression Lysate (Denatured) - H00004969-T02 from Novus Biologicals
|
||||||||
Panoply™ Human OGN Knockdown Stable Cell Line - CSC-DC010824 from Creative biogene
|
||||||||